Skip to content
S8423Senate2021-2022 SessionSame asA9580

No Delays for HIV Drugs

Official title

“Prohibits the preferred drug program, managed care programs and insurers from restricting or imposing delays in the distribution of antiretroviral prescription drugs prescribed to a person for HIV or AIDS”

Sponsor Brad Hoylman-SigalSD-27+3 co-sponsorsAffects Health
Status
In Senate Committee
Health
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill prohibits New York health plans, managed care, and insurers from imposing restrictions or delays on dispensing HIV/AIDS antiretroviral drugs.

Why it matters

  1. Removes administrative barriers. for people seeking HIV/AIDS antiretroviral drugs by eliminating prior authorization and step therapy requirements, potentially allowing for quicker and more reliable access to essential medications.

  2. Addresses public health and equity concerns. by ensuring that all New Yorkers—regardless of insurance type or whether they are covered by Medicaid, managed care, or private plans—have the same immediate access to HIV prevention and treatment drugs.

  3. May help reduce HIV transmission rates and improve health outcomes. by making it easier for patients to start and continue antiretroviral regimens without interruption or bureaucratic delay, which is critical for both individual and community health.

  4. Limits insurer and plan discretion. in managing antiretroviral drug costs, which could have financial implications for health plans but prioritizes patient access and continuity of care over cost-containment strategies.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

No Delays for HIV Drugs

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Brad Hoylman-Sigal

Senator · Senate District 27

Chair, Judiciary

History

  1. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A9580Assembly

Protect HIV Drug Access

In Assembly Committee · Insurance · Sponsor Linda Rosenthal

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8423

IN SENATE

February 28, 2022

Introduced by Sen. HOYLMAN -- read twice and ordered printed, and when printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation to prohibiting the preferred drug program from restricting or imposing delays in the distribution of antiretroviral prescription drugs to certain persons; to amend the social services law, in relation to prohibiting managed care programs from restricting or imposing delays in the distribution of antiretroviral prescription drugs to certain persons; and to amend the insurance law, in relation to prohibiting insurers from restricting or imposing delays in the distribution of antiretroviral prescription drugs to certain persons

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Section 273 of the public health law is amended by adding a new subdivision 11 to read as follows:

11. No prior authorization, step therapy, or any other protocol that could restrict or delay the dispensing of the drug shall be required for antiretroviral prescription drugs prescribed to a person in a state public health plan for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).

§ 2. Section 364-j of the social services law is amended by adding a new subdivision 26-d to read as follows:

26-d. Managed care providers shall not subject an antiretroviral prescription drug prescribed to a person for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) to a prior authorization requirement, step therapy, or any other protocol that could restrict or delay the dispensing of the drug.

§ 3. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 36 to read as follows:

(36) No policy that provides coverage for antiretroviral prescription drugs prescribed for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) shall subject such drugs to prior authorization requirement, step therapy, or

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD14725-01-2

any other protocol that could restrict or delay the dispensing of the drug.

§ 4. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 21 to read as follows:

(21) Every group or blanket policy delivered or issued for delivery in this state that provides coverage for antiretroviral prescription drugs for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) shall not subject such drug to a prior authorization requirement, step therapy, or any other protocol that could restrict or delay the dispensing of the drug.

§ 5. Section 4303 of the insurance law is amended by adding a new subsection (ss) to read as follows:

(ss) Any contract issued by a medical expense indemnity corporation, a hospital service corporation or a health services corporation that provides coverage for antiretroviral prescription drugs for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) shall not subject such drug to a prior authorization requirement, step therapy, or any other protocol that could restrict or delay the dispensing of the drug.

§ 6. This act shall take effect on the first of January next succeeding the date on which it shall have become a law; provided, however, that sections three, four and five of this act shall apply to all coverage, contracts or policies issued, reissued, renewed, modified, altered or amended on or after such effective date; and provided further, however, that the amendments to section 364-j of the social services law made by section two of this act, shall not affect the repeal of such section and shall be deemed repealed therewith. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to prohibiting the preferred drug program from restricting or imposing delays in the distribution of antiretroviral prescription drugs to certain persons; to amend the social services law, in relation to prohibiting managed care programs from restricting or imposing delays in the distribution of antiretroviral prescription drugs to certain persons; and to amend the insurance law, in relation to prohibiting insurers from restricting or imposing delays in the distribution of antiretroviral prescription drugs to certain persons

Purpose or general idea of bill

Prohibits insurers and public health plans from utilizing prior authori- zation, step therapy, or other protocols that would restrict access to antiretroviral drugs for the treatment or prevention of HIV or AIDS

Summary of provisions

Section one prohibits the utilization of prior authorization, step ther- apy or any other protocol that would restrict or delay the dispensing of an antiretroviral drug for the treatment or prevention of HIV or AIDS in the preferred drug program.

Read the full memo (760 words)

Section two prohibits Medicaid managed care plans from utilizing prior authorization, step therapy or any other protocol that would restrict or delay the dispensing of an antiretroviral drug for the treatment of HIV or AIDS.

Sections three through five prohibit insurance policies, group or blan- ket insurance plans, medical indemnity corporation, hospital service corporations or a health service corporation that provide coverage for antiretroviral drugs for the treatment of HIV or AIDS from subjecting these drugs to prior authorization, step therapy, or other protocols that would restrict or delay the dispensing of the drug.

Section six is the effective date.

Justification

The "Ending the Epidemic" blueprint and subsequent progress report note that providing better, more immediate access to antiretroviral drugs is a key tool in fighting the AIDS epidemic.Patient needs vary with each individual and health care providers consider a broad range of factors when selecting treatments including the patient's drug resistance profile, comorbidities, interactions with other medications, and pill burden, in order to determine the most appropriate treatment. A person living with HIV who is on effective HIV treatment can live a long and health life and have effectively no risk of sexually transmitting HIV to others. Additionally, a person at risk for HIV who is on effective HIV prevention medication can reduce their risk of getting HIV by 99% when taking the medication as prescribed.

New York enacted an Antiretroviral (ARV) protected class law in 2005. The 2011 final enacted state budget carved the drug benefit out of fee- for-service and into managed care, and removed statutory protections for ARVs and other drugs, leaving the HIV community with restricted access and life-threatening delays. Because these protections were rolled back, insurers now use protocols such as prior authorization or fail first (step therapy) protocols in order to minimize prescription drug costs. These protocols have the effect of delaying access to these critically important, time-sensitive drugs which are particularly harmful for indi- viduals who are currently living with, or seeking to prevent HIV infection.

Restricting access to these life-saving medications undermines the relationship between a healthcare provider and their patient and puts up unnecessary roadblocks to prevention and treatment. Specifically with HIV treatment, the ability for the patient and medical professional to rapidly switch antiretroviral medications is key to effectively treat- ing, and stopping the spread of HIV and AIDS.

Patients should have open access to all Single Tablet Regimens (STRs) to fully benefit from current and future advances in HIV therapy. A large body of evidence demonstrates that individuals on STR's have higher levels of adherence to HIV treatment, which improves health outcomes, lowers the risk of hospitalization and reduces overall healthcare costs. Studies show that individuals on STRs within the Veterans Affairs health system, had 46% fewer hospitalizations compared to patients on Multi-ta- blet Regimens (MTRs) and were 21% more likely to have undetectable levels of HIV in the body. Open access to appropriate HIV prevention and treatment medication for HIV will also support health equity by ensuring that all New Yorkers have their treatment needs met regardless of their insurance plan.This bill will ensure that these important anti-retrovi- ral medications are readily available to patients and not subject to procedural delays so that patients can start an HIV treatment regimen as soon as they are diagnosed or exposed to possible infection.

Prior legislative history

New Bill

Fiscal implications for state and local governments

None.

Effective date

This act shall take effect on the first of January next succeeding when it becomes a law.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.